Bold Moves

Lead the conversation

Unleash the power of our people

Pfizer’s commitment to the breast cancer community is unwavering

This year, Pfizer announced results from two studies of Ibrance®(palbociclib) – our breakthrough medicine for metastatic breast cancer – in earlier stages of the disease. These collaborative research studies were conducted by international cooperative research groups and were designed to evaluate whether the addition of palbociclib to standard endocrine treatment would reduce the risk of developing recurrent disease for patients with early HR+/HER2- breast cancer. Neither the PALLAS nor the PENELOPE-B studies showed an incremental benefit from the addition of palbociclib to standard endocrine therapy for people with early-stage breast cancer.

Pfizer scientists, like Sabrina Maisel, work relentlessly to advance breakthrough treatments for people living with cancer.

While these results were disappointing, the study results provide opportunities to learn more about the heterogeneous biology of early breast cancer and enhance future research. The palbociclib early breast cancer development program represents how collaborative partnerships can help advance science, and despite the negative study outcomes, we can learn, evolve and continue to innovate.

The learnings from these studies will be valuable as we continue to advance the development of our investigational next-generation CDK inhibitor programs.

350,000 ​​​​​​​​​​​​

Since first approval in 2015, Ibrance has been prescribed to nearly 350,000 patients around the world and is approved in 101 countries.

Our commitment to women and men living with breast cancer remains steadfast. We are proud of the transformative impact Ibrance has on the treatment of HR+, HER2- metastatic breast cancer (MBC) – a disease with a vastly different prognosis and goals of therapy than early breast cancer. This year we achieved the 101st worldwide approval for Ibrance combination therapy in the treatment of certain patients with MBC and to date, Ibrance has been prescribed to more than 350,000 people around the world.  We look forward to continuing to learn from patients’ real-world experience through evaluation of data from everyday clinical practice to further inform treatment decisions.

​​​​​​​As we reflect on the past year, it is important we continue to follow the science on the path to better outcomes for patients.

Discover more

Advances for a Potential First-in-Class Chronic OA Pain Treatment

Advancing Breakthroughs for Patients With NASH

Eucrisa, Now Starring Jessica Simpson

Working for Patients with Alopecia Areata

Advancing a Potential Breakthrough for Moderate to Severe Atopic Dermatitis

A Potentially Practice-Changing Approval in Advanced Urothelial Cancer

Addressing an Unmet Need for Certain Patients With BRAF-Mutant mCRC

Learning From Early Breast Cancer Studies to Drive Oncology Research Forward

Cancer Doesn’t Wait: Supporting Screenings During COVID-19

Positive Phase 1/2 Data at One Year for Hemophilia A Gene Therapy

Investigational Gene Therapy for Duchenne Muscular Dystrophy Achieves Exciting Milestones in 2020

Pfizer Vaccines Pipeline Includes Six Late-Stage Candidates

Pfizer Vaccines Launches​​​​​​​ Global Centers of Excellence Network

Progressing Maternal Vaccination Against Respiratory Syncytial Virus

Pfizer Pledges $100 Million Into New AMR Industry Fund

Partnering with Wellcome to Combat AMR in Sub-Saharan Africa

Expanding Access in China Through Health Insurance Innovation

Pfizer Invests in Biotechnology Innovation through the Pfizer Breakthrough Growth Initiative

Hospital Donations for COVID-19 Response

Pfizer Partners with BioNTech to Advance & Supply COVID-19 Vaccine​​​​​​​

Delivering on the Promise of Biosimilars

Driving Diversity in Our Research and Development​​​​​​​

Site Feature: Puurs, Belgium 

PGS Ingenuity Solves COVID-19 Cold Chain Storage Challenge​​​​​​​

Pfizer and Gilead Sciences Agree to Manufacture and Supply Remdesivir​​​​​​​

Key Medicine Supply and Public Policy During COVID-19

Pfizer Stands with Science

Five-Point Plan for Unprecedented Collaboration

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on Pfizer.com.

Visit Pfizer.com


Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories